High Grade B Cell Lymphoma With Myc And Or Bcl2 And Or Bcl6 Rearrangement C4524190
A highly aggressive lymphoma with specific genetic rearrangements involving MYC, BCL2, and/or BCL6 genes. It requires intensive treatment and has a challenging outlook.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Rapidly enlarging lymphadenopathy
Unexplained weight loss
Neurological deficits due to CNS involvement
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Night sweats
(General)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Dose-adjusted EPOCH-R regimen
Intensive continuous infusion chemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab. This dose-dense approach is preferred for double/triple-hit lymphomas due to their aggressive nature.
R-HyperCVAD regimen
Alternating cycles of rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with high-dose methotrexate and cytarabine. Alternative intensive approach for MYC-rearranged lymphomas.
Additional treatment options
CAR-T cell therapy
Chimeric antigen receptor T-cell therapy targeting CD19 for patients with refractory or relapsed disease after chemotherapy. Patient's T-cells are engineered to recognize and attack lymphoma cells.
procedureTargeted therapy with BTK inhibitors
Agents such as ibrutinib may be incorporated into treatment regimens or used in combination approaches for this high-risk lymphoma subtype with promising activity in early studies.
medicationIntensive response monitoring
Frequent imaging with PET-CT, serial biopsies for molecular assessment, and comprehensive laboratory monitoring to evaluate treatment efficacy and detect early relapse given the high-risk nature of this lymphoma.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is High Grade B Cell Lymphoma With Myc And Or Bcl2 And Or Bcl6 Rearrangement C4524190?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat High Grade B Cell Lymphoma With Myc And Or Bcl2 And Or Bcl6 Rearrangement C4524190. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy